Aim: The association between small dense low-density lipoprotein cholesterol (sdLDL-C) levels and carotid intimal medial thickness (cIMT) progression has not been evaluated fully. We assessed specialized lipoproteins, including sdLDL-C, with regard to cIMT progression in a prospective observational study in Japan.

Methods: Plasma total cholesterol, direct LDL-C, sdLDL-C, LDL-triglycerides (LDL-TG), high-density lipoprotein cholesterol (HDL-C), HDL2-C, HDL3-C, triglycerides, Lp(a), and adiponectin were measured in 2,030 men and women (median age 59 years, free of cardiovascular disease (CVD) and off cholesterol lowering medication). At both baseline and after a five-year follow-up, cIMT was assessed. Univariate, multivariate regression, and least square analyses were performed to examine the relationships between direct LDL-C, sdLDL-C, and other lipoproteins with cIMT progression.

Results: The median cIMT at baseline was 0.63 mm and five-year progression was 0.18 mm. After adjustment for standard CVD risk factors, including age, gender, systolic blood pressure, total cholesterol, HDL-C, smoking, diabetes, and hypertension treatment, only direct LDL-C, sdLDL-C, and the sdLDL-C/LDL-C ratio were associated with cIMT progression. Even in subjects with direct LDL-C <100 mg/dL, who were considered at low CVD risk, elevated sdLDL-C were associated with cIMT progression (P for trend = 0.009) in a model with established CVD risk factors, although the sdLDL-C/LDL-C ratio did not. Those correlations did not change by including triglycerides as a controlling factor or excluding premenopausal women from the analyzed population.

Conclusions: Small dense LDL-C has a stronger relationship with cIMT progression than LDL-C does; therefore, measuring sdLDL-C may allow for the formulation of optimal therapy for CVD prevention.

Key words: Small dense LDL cholesterol, Carotid intimal medial thickness, Cardiovascular diseases, Atherosclerosis

Abbreviations: CVD; cardiovascular disease, HDL-C; high-density lipoprotein cholesterol, LDL-C; low-density lipoprotein cholesterol, sdLDL-C; small dense low-density lipoprotein cholesterol, lbLDL-C; large buoyant low-density lipoprotein cholesterol, cIMT; carotid intimal medial thickness, KOPS; Kyushu and Okinawa Population Study, hsCRP; high sensitivity C reactive protein, LDL-TG; low-density lipoprotein triglycerides, Lp(a); lipoprotein(a)

1. Introduction

Cardiovascular disease (CVD) is a leading cause of death and disability worldwide1). According to the American Heart Association / American College of Cardiology guidelines, major CVD risk factors include increased age, male gender, hypertension, diabetes, smoking, increased total cholesterol, and decreased high-density lipoprotein cholesterol (HDL-C)2). Increased low-density lipoprotein cholesterol (LDL-C)
is also a CVD risk factor highly associated with total cholesterol. An LDL-C target value of <70mg/dL has been recommended for patients with established CVD in the United States and <100 mg/dL in Japan. In many laboratories, LDL-C is calculated using the Friedewald formula or the Martin formula; however, this estimated LDL-C is inaccurate if the subject has not fasted for at least eight hours or if the plasma triglycerides concentration is >400 mg/dL. Moreover, our studies indicate that, even if triglycerides concentration is >200 mg/dL, the estimated LDL-C value becomes increasingly inaccurate compared to LDL-C levels measured with ultracentrifugation methods. Direct homogeneous LDL-C assays for use on an automated analyzer without sample pretreatment were developed. The values obtained with these assays correlated well with results obtained with the reference method using ultracentrifugation. Small dense LDL-C (sdLDL-C) is a subfraction of LDL with a density of 1.044-1.063 g/mL. Studies indicate that sdLDL-C is associated with a higher CVD risk than large buoyant LDL-C (lbLDL-C). Our prior studies found that elevated sdLDL-C levels were significantly associated with increased triglycerides and decreased HDL-C levels in the Framingham Offspring Study. However, the measurement methods of low-density lipoprotein particles in these studies used gradient gel electrophoresis, which is cumbersome, labor-intensive, and difficult to reproduce. Subsequently, a direct homogeneous automated assay for measuring sdLDL-C was developed. Elevated sdLDL-C, measured using this homogeneous method, has been strongly associated with the presence of coronary heart disease and risk factors.

Measuring carotid intimal medial thickness (cIMT) by carotid ultrasonography is an excellent method of assessing for the presence of atherosclerosis, and is an excellent measure of CVD risk. Increased cIMT, noninvasively measured by B-mode ultrasonography, is associated with carotid arterial wall stiffness, CVD event, and severe coronary atherosclerosis. Elevated LDL-C levels correlate with atherosclerosis development, and several studies have associated elevated sdLDL-C levels with increased cIMT. However, these studies were all cross-sectional and, to our knowledge, there has been no prospective study to assess the association of sdLDL-C levels with cIMT progression.

In this investigation, our goal was to examine the clinical utility of sdLDL-C and LDL-C, using direct homogeneous assays as well as other atherogenic lipoproteins, for predicting cIMT progression in a prospective, observational, community-based cohort study.

2. Subjects and Methods

2.1 Study Population and Design

Subjects in this study were participants of the Kyushu and Okinawa Population Study (KOPS), a community-based, prospective, observational study of lifestyle-related diseases and cancers, which has been underway since 2004. A total of 18,762 participants have been enrolled in KOPS, and the population is almost entirely Japanese. For this analysis, we included 2,030 male and female participants who gave blood samples after an overnight fast at the baseline survey, had cIMT measured, and were not taking cholesterol lowering medications during baseline and five-year follow-up surveys. They also had physical examinations, including measurement of blood pressure, height, and weight as part of their participation in this study. All participants provided their past medical history, including information about hospitalization, use of all medications, and lifestyle habits. Each participant provided informed consent prior to enrollment. To ensure data validity, all doctors who participated in the study were staff members of the Department of General Internal Medicine of Kyushu University Hospital, who had been trained with regard to the study protocol and the medical procedures. All studies were carried out in accordance with the principles of the Declaration of Helsinki, as revised in 2008, and approved by the Kyushu University Hospital Ethics Committee prior to data collection.

2.2 Laboratory Measurements

Fasting plasma samples were stored at −80°C and not thawed until use. Plasma levels of total cholesterol, HDL-C, triglycerides, high sensitivity C reactive protein (hsCRP) were measured with standard enzymatic methods, as previously described. Plasma levels of direct LDL-C, sdLDL-C, LDL-triglycerides (LDL-TG), adiponectin, lipoprotein(a) [Lp(a)], and HDL-C were determined using homogeneous assay kits obtained from Denka-Seiken (Niigata, Japan) on an automated chemistry analyzer (Olympus AU400), as previously described. All analyses were carried out...
in the central laboratory at Tufts University, and the within- and between-run coefficients of variation for all assays were <5.0 %. Non-HDL-C, calculated LDL-C, lbLDL-C, and HDL2-C were calculated as follows: 1) non-HDL-C=total cholesterol – HDL-C; 2) calculated LDL-C=total cholesterol – (HDL-C+ TG/5); 3) lbLDL-C=direct LDL-C – sdLDL-C; and 4) HDL2-C=HDL-C – HDL3-C. Ratios of sdLDL-C to LDL-C were calculated as the sdLDL-C value divided by the direct LDL-C or calculated LDL-C value.

2.3 Assessments of Carotid Intimal Medial Thickness

cIMT levels were measured by B-mode ultrasonography (UF-400AX, Fukuda Denshi, Co., Ltd., Tokyo, Japan) with a 10 MHz probe. All ultrasound examinations focused on the far wall of both the left and right common carotid arteries and were performed by 10 well-trained staff doctors from our department. Images were obtained 20 mm proximal to the bulb origin and analyzed off-line using innovative IMT measurement software (Intima-Scope; MEDIA CROSS Co., Ltd., Tokyo, Japan). This system was specifically designed to assess carotid intimal medial thickness levels and allows one to obtain the average of approximately 250 points of cIMT values in the measurement segment in the order of 0.01 mm. Segments with plaque were excluded from assessment of cIMT levels. Analyzing cIMT levels using Intima-Scope was performed by a well-trained technician who was blinded to the clinical information. In this study, subjects had their cIMT values assessed at baseline and five-year follow-up, and the differences between those two surveys were calculated.

2.4 Statistical Analyses

All statistical analyses were performed using SAS 9.4 (SAS Institute Inc., Cary, NC). Data are expressed as median values with 25th and 75th percentile values. Categorical variables are reported as frequencies and percentages. Univariate analyses were carried out using Mann-Whitney U testing for continuous variables between groups or Chi-square testing for categorical variables. Univariate and multivariate regression analyses were performed to examine associations with cIMT change over the five-year period and the biochemical variables. In addition, we modeled sdLDL-C as a categorical variable by quartiles, and the cut-points were obtained from the sdLDL-C distribution in the whole population (25th, 50th, and 75th percentile values were 15.2, 21.6, and 30.7 mg/dL, respectively). The P values for trends in multivariate adjustment factors were evaluated with linear or logistic regression and adjusted for standard CVD risk factors, include age, gender, systolic blood pressure, total cholesterol, HDL-C, current smoking, hypertension treatment, and diabetes. Spearman’s correlation coefficient was used to assess the correlations of sdLDL-C and traditional CVD risk factors and other lipoproteins. All laboratory measurement variables were log-transformed to account for their non-Gaussian distributions. Associations between the sdLDL-C or sdLDL-C/LDL-C ratio and cIMT change over five years were assessed using least square methods and the Jonckheere-Terpstra trend test, with adjustment for standard CVD risk factors. A P value of <0.05 was considered statistically significant.

3. Results

3.1 Characteristics at Baseline

Table 1 shows descriptive information on the 2,030 participants at baseline, including information about menopausal status. The mean age was 59 years, and 62.2 % were women. Among the 1,263 women, 187 (14.8%) were premenopausal. Of a total of 2,030 subjects, 1,263 women and 767 men, 242 (11.9%) were smokers, 302 (14.9 %) had hypertension, 279 (13.7 %) were taking blood pressure lowering medication, 50 (2.5 %) had diabetes mellitus, and 42 (2.1 %) were taking diabetes medication. None of subjects were taking lipid lowering medications. Mean cIMT levels were 0.63 mm, and the men had significantly higher cIMT levels than the women (P<0.001). The mean sdLDL-C levels were 21.6 mg/dL, and the men had significantly higher sdLDL-C levels than the women (P<0.001). The mean direct LDL-C levels were 91 mg/dL, and the men had significantly higher direct LDL-C values than the women (P=0.02). Mean sdLDL-C/direct LDL-C ratios were 23.5 %, and the men had significantly higher sdLDL-C/direct LDL-C ratio than the women (P<0.001). The women had significantly higher levels of HDL-C, HDL3-C, and HDL2-C than the men (all P<0.001). They also had significantly higher non-HDL-C levels than the men (P<0.01). Comparing men and post-menopausal women, similar differences were observed; instead of direct LDL-C, they had almost same direct LDL-C levels (P=0.97).

3.2 Regression Analyses for cIMT Changes

Table 2 provides results of univariate and multivariate regression analyses for cIMT changes over five years. The mean cIMT changes were 0.18 mm. On univariate analyses, higher levels of sdLDL-C, direct LDL-C, sdLDL-C/LDL-C ratio, LDL-TG, triglycerides, Lp(a), and non-HDL-C were significantly and
positively associated with cIMT progression (all \(P<0.05\)). The univariate analysis parameters that were most strongly associated with an estimated value for cIMT change >0.10, in order, included 1) sdLDL-C/LDL-C ratio, 2) direct LDL-C, 3) sdLDL-C, 4) gender, 5) diabetes treatment, 6) diabetes, 7) log triglycerides, 8) hypertension, and 9) hypertension treatment. HDL-C, HDL3-C, HDL2-C, and adiponectin were significantly negatively associated with cIMT progression (all \(P<0.05\)). Among these parameters, HDL-C had the lowest estimated value for cIMT change, followed by 2) HDL2-C, 3) HDL3-C, and 4) adiponectin. After controlling for standard CVD risk factors, such as age, gender, systolic blood pressure, smoking, hypertension treatment, diabetes, total cholesterol, and HDL-C, only sdLDL-C, direct LDL-C, and sdLDL-C/LDL-C ratio were significantly (estimated values were 0.227, 0.306, and 0.455, respectively, and \(P<0.001, P=0.02,\) and \(P<0.01,\) respectively) positively correlated with cIMT change, and BMI had significant negative correlation with cIMT change (estimated value was −0.010 and \(P<0.01\)). Therefore,

| Table 1. Characteristics at baseline, classified by sex and menopausal status* |
|-----------------------------------------------|
| **Variables at baseline**                      | **Men** (\(n=767\)) | **Women** (\(n=1,263\)) | **Postmenopausal** | **P value** |
| **Age (year)**                                | 61 [52, 67] | 58 [50, 65] | 40 [35, 43] | 60 [54, 66] | <0.001 |
| **Body mass index (kg/m²)**                   | 24.2 [22.3, 26.4] | 23.2 [21.0, 25.5] | 21.4 [19.8, 23.8] | 23.5 [21.3, 25.8] | <0.001 |
| **Systolic blood pressure (mmHg)**            | 128 [118, 138] | 122 [110, 135] | 109 [100, 116] | 124 [112, 136] | <0.001 |
| **Diastolic blood pressure (mmHg)**           | 78 [70, 84] | 71 [66, 80] | 60 [60, 73] | 72 [68, 80] | <0.001 |
| **Current smoking, n (%)**                    | 184 [26.7] | 58 [5.3] | 20 [12.4] | 38 [4.1] | <0.001 |
| **Current alcohol drinking, n (%)**           | 443 [67.8] | 233 [22.4] | 65 [40.6] | 168 [19.1] | <0.001 |
| **Hypertension, n (%)**                       | 137 [19.8] | 165 [14.9] | 1 [0.6] | 164 [17.5] | <0.01 |
| **Hypertension treatment, n (%)**             | 123 [17.3] | 156 [13.1] | 1 [0.5] | 155 [14.5] | <0.01 |
| **Diabetes, n (%)**                           | 32 [4.6] | 18 [1.6] | 0 [0.0] | 18 [1.9] | 0.09 |
| **Diabetes treatment, n (%)**                 | 27 [3.8] | 15 [1.3] | 0 [0.0] | 15 [1.5] | 0.15 |
| **Total cholesterol (mg/dL)**                 | 176 [157, 195] | 186 [168, 205] | 164 [147, 183] | 190 [172, 208] | <0.001 |
| **Triglycerides (mg/dL)**                     | 116 [81, 170] | 96 [68, 137] | 71 [53, 106] | 100 [71, 142] | <0.001 |
| **HDL-C (mg/dL)**                             | 55 [48, 65] | 63 [54, 74] | 66 [56, 75] | 63 [53, 74] | 0.053 |
| **Non HDL-C (mg/dL)**                         | 119 [99, 138] | 121 [102, 140] | 97 [82, 117] | 125 [107, 143] | <0.001 |
| **Calculated LDL-C (mg/dL)**                  | 90 [74, 109] | 100 [82, 116] | 80 [66, 97] | 102 [86, 118] | <0.001 |
| **Direct LDL-C (mg/dL)**                      | 93 [76, 114] | 91 [73, 109] | 74 [60, 92] | 93 [77, 112] | <0.001 |
| **Small dense LDL-C (mg/dL)**                 | 24.3 [16.8, 33.6] | 20.4 [14.3, 28.6] | 14.6 [10.2, 23.6] | 21.0 [15.3, 29.1] | <0.001 |
| **Small dense LDL-C / calculated LDL-C ratio** | 25.6 [19.3, 36.3] | 19.8 [15.4, 27.8] | 18.1 [13.4, 28.2] | 19.9 [15.6, 27.8] | <0.001 |
| **Large buoyant LDL-C (mg/dL)**               | 67.0 [56.1, 80.0] | 68.7 [57.4, 81.5] | 58.4 [47.1, 67.0] | 70.6 [59.6, 82.9] | <0.001 |
| **VLDL-C (mg/dL)**                            | 23 [13.3] | 30 [20.4] | 23 [11.34] | 31 [21.41] | <0.001 |
| **LDL-triglycerides (mg/dL)**                 | 10.1 [6.4, 15.8] | 7.5 [4.7, 11.9] | 5.6 [3.9, 9.1] | 7.7 [4.9, 12.2] | <0.001 |
| **HDL3-C (mg/dL)**                            | 13.9 [11.2, 17.2] | 14.5 [12.1, 18.8] | 14.2 [11.7, 18.5] | 14.5 [12.2, 18.8] | 0.35 |
| **HDL2-C (mg/dL)**                            | 40.8 [33.4, 50.2] | 47.5 [38.7, 58.7] | 49.1 [42.5, 61.6] | 47.3 [38.1, 58.6] | 0.01 |
| **Lipoprotein (a) (µg/mL)**                   | 6.2 [3.3, 11.8] | 7.3 [4.0, 13.3] | 6.1 [3.1, 10.6] | 7.5 [4.1, 13.5] | <0.01 |
| **Adiponectin (µg/mL)**                       | 5.6 [3.8, 8.1] | 9.6 [6.9, 12.9] | 8.2 [6.2, 11.1] | 9.8 [7.1, 13.2] | <0.001 |
| **High sensitivity CRP (mg/L)**               | 0.44 [0.21, 0.82] | 0.38 [0.15, 0.80] | 0.22 [0.09, 0.50] | 0.42 [0.18, 0.84] | <0.001 |
| **Mean cIMT at baseline (mm)**                | 0.67 [0.60, 0.77] | 0.63 [0.57, 0.70] | 0.53 [0.47, 0.60] | 0.65 [0.58, 0.73] | <0.001 |

*Data are shown as median [25% quartile, 75% quartile] or number (%).

1) P values were calculated between women and men groups.

2) P values were calculated between premenopausal and postmenopausal women groups.

3) Parameter is calculated using the following equation: total cholesterol – HDL-C.

4) Parameter is calculated using the following Friedewald equation: (total cholesterol – HDL-C) – (triglycerides/5).

5) Parameter is calculated using the following equation: LDL-C – small dense LDL-C.

6) **Parameter is calculated using the following equation: total cholesterol – HDL-C – LDL-C.**

7) **Parameter is calculated using the following equation: HDL-C – HDL3-C.**

8) **HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; VLDL-C, very low-density lipoprotein cholesterol; CRP, C reactive protein; cIMT, carotid intimal medial thickness.**
Table 2. Regression analyses for cIMT changes during 5 years

| Variables                                         | Univariate | Multivariate Model 1 | Multivariate Model 2 |
|---------------------------------------------------|------------|----------------------|----------------------|
|                                                   | Adjusted R² | Estimated P value    | Adjusted R² | Estimated P value    | Adjusted R² | Estimated P value    |
| Age (/ 1 year)                                    | 0.0700     | 0.011 < 0.001        | 0.0926     | -0.010 < 0.01        | 0.0935     | -0.010 < 0.01        |
| Sex (men)                                         | 0.0378     | 0.187 < 0.001        |            |                      |            |                      |
| Body mass index (/ 1 kg/m²)                       | -0.0002    | 0.002 0.44           | 0.0926     | -0.010 < 0.01        | 0.0935     | -0.010 < 0.01        |
| sBP (/ 1 mmHg)                                    | 0.0205     | 0.004 < 0.001        |            |                      |            |                      |
| dBP (/ 1 mmHg)                                    | 0.0040     | 0.003 < 0.01         | 0.0892     | < -0.001 0.69        | 0.0895     | < -0.001 0.64        |
| Current smoking (yes)                             | 0.0026     | 0.073 0.02           |            |                      |            |                      |
| Current alcohol drinking (yes)                    | 0.0071     | 0.080 < 0.001        | 0.0888     | 0.033 0.18           | 0.0889     | 0.030 0.23           |
| Hypertension (yes)                                | 0.0102     | 0.122 < 0.001        |            |                      |            |                      |
| Hypertension treatment (yes)                      | 0.0085     | 0.116 < 0.001        |            |                      |            |                      |
| Diabetes (yes)                                    | 0.0030     | 0.158 0.01           |            |                      |            |                      |
| Diabetes treatment (yes)                          | 0.0026     | 0.163 0.01           |            |                      |            |                      |
| log total cholesterol (/ 1 log)                   | -0.0002    | -0.117 0.43          |            |                      |            |                      |
| log triglycerides (/ 1 log)                       | 0.0059     | 0.155 < 0.001        | 0.0895     | 0.073 0.16           |            |                      |
| log HDL-C (/ 1 log)                               | 0.0056     | -0.338 < 0.001       |            |                      |            |                      |
| log non HDL-C⁻¹ ( / 1 log)                        | 0.0004     | 0.128 0.18           |            |                      |            |                      |
| log calculated LDL-C⁻¹ ( / 1 log)                 | -0.0003    | -0.052 0.52          |            |                      |            |                      |
| log direct LDL-C ( / 1 log)                       | 0.0045     | 0.251 < 0.01         |            |                      |            |                      |
| log small dense LDL-C ( / 1 log)                  | 0.0127     | 0.245 < 0.001        |            |                      |            |                      |
| Small dense LDL-C / calculated LDL-C ratio ( / 1%)| 0.0168     | 0.353 < 0.001        |            |                      |            |                      |
| Small dense LDL-C / direct LDL-C ratio ( / 1%)    | 0.0147     | 0.727 < 0.001        |            |                      |            |                      |
| log large buoyant LDL-C⁻¹ ( / 1 log)              | -0.0001    | 0.067 0.40           |            |                      |            |                      |
| log VLDL-C⁻¹ ( / 1 log)                           | 0.0031     | -0.009 < 0.01        |            |                      |            |                      |
| log LDL-triglycerides ( / 1 log)                  | 0.0027     | 0.088 0.01           |            |                      |            |                      |
| log HDL3-C ( / 1 log)                             | 0.0027     | -0.199 0.01          |            |                      |            |                      |
| log HDL2-C* ( / 1 log)                            | 0.0043     | -0.240 < 0.01        |            |                      |            |                      |
| log lipoprotein(a) ( / 1 log)                     | 0.0007     | 0.039 0.11           |            |                      |            |                      |
| log adiponectin ( / 1 log)                        | 0.0025     | -0.101 0.01          |            |                      |            |                      |
| log high sensitivity CRP ( / 1 log)               | 0.0013     | 0.039 0.06           |            |                      |            |                      |

*Variables in multivariate regression analyses model 1 were adjusted for age, sex, systolic blood pressure, total cholesterol, high density lipoprotein cholesterol, current smoking, history of diabetes, and hypertension treatment.

1Variables in multivariate regression analyses model 2 were adjusted for age, sex, systolic blood pressure, total cholesterol, high density lipoprotein cholesterol, current smoking, history of diabetes, and hypertension treatment and triglycerides.

Parameter is calculated using the following equation: total cholesterol – HDL-C.

Parameter is calculated using the following Friedewald equation: (total cholesterol – HDL-C) – (triglycerides/5).

Parameter is calculated using the following equation: LDL-C – small dense LDL-C.

Parameter is calculated using the following equation: total cholesterol – LDL-C – LDL-C.

**Parameter is calculated using the following equation: HDL-C – HDL3-C.

Table 2 shows the means or proportions of CVD risk factors and lipoproteins by sdLDL-C quartiles. On univariate analyses for standard CVD risk factors, individuals with the highest sdLDL-C levels were more likely to be older men with higher systolic blood pressure and total cholesterol levels, hypertension, and diabetes, and receiving hypertension treatment. In addition, they were more likely to have lower HDL-C levels (all P<0.05). On multivariate analyses, with adjustment for standard CVD risk factors, individuals

only sdLDL-C and direct LDL-C were statistically significant lipoproteins for cIMT progression. Adding TG to the controlling factors did not change those correlations. In addition, those results were not different when excluding 187 premenopausal women.

3.3 Association of sdLDL-C with Cardiovascular Risk Factors and Other Lipoproteins

Table 3 shows the means or proportions of CVD risk factors and lipoproteins by sdLDL-C quartiles.
Table 3. Parameters by quartiles of small dense LDL-C and P-value for trend across quartiles, adjusted for standard ASCVD risk factors

| Small dense LDL-C Quartiles | Quartile 1 (n = 507) | Quartile 2 (n = 506) | Quartile 3 (n = 510) | Quartile 4 (n = 507) | P values for trend |
|-----------------------------|----------------------|----------------------|----------------------|----------------------|-------------------|
| Unadjusted variables‡      |                      |                      |                      |                      |                   |
| Age (years)                 | 56 [46, 63]          | 59 [52, 66]          | 60 [53, 67]          | 61 [50, 68]          | <0.001            |
| Women, n (%)                | 361 (71.2)           | 339 (67.0)           | 300 (58.8)           | 263 (51.9)           | <0.001            |
| Systolic blood pressure (mmHg) | 120 [109, 132]      | 122 [112, 136]      | 125 [116, 136]      | 128 [116, 139]      | <0.001            |
| Total cholesterol (mg/dL)   | 164 [148, 181]       | 180 [162, 197]       | 189 [171, 205]       | 198 [182, 215]       | <0.001            |
| HDL-C (mg/dL)               | 67 [57, 78]          | 63 [54, 75]          | 58 [49, 67]          | 54 [47, 63]          | <0.001            |
| Current smoking, n (%)      | 51 (11.8)            | 60 (13.7)            | 62 (13.6)            | 68 (15.2)            | 0.53              |
| Hypertension, n (%)         | 56 (12.5)            | 82 (18.5)            | 76 (16.6)            | 88 (19.6)            | 0.02              |
| Hypertension treatment, n (%) | 50 (10.3)          | 76 (15.9)            | 72 (15.1)            | 81 (17.5)            | <0.01             |
| Diabetes, n (%)             | 10 (2.2)             | 9 (2.0)              | 11 (2.4)             | 20 (4.4)             | 0.13              |
| Diabetes treatment, n (%)   | 9 (1.9)              | 8 (1.7)              | 9 (1.9)              | 16 (3.5)             | 0.25              |
| Adjusted variables§         |                      |                      |                      |                      |                   |
| Body mass index (kg/m²)     | 23.5 ± 0.3           | 24.3 ± 0.3           | 24.5 ± 0.3           | 24.9 ± 0.3           | <0.001            |
| Diastolic blood pressure (mmHg) | 73.7 ± 0.7          | 73.2 ± 0.7           | 73.8 ± 0.7           | 75.0 ± 0.7           | 0.02              |
| Current alcohol drinking (%) | 39.0 ± 4.1           | 41.3 ± 3.9           | 50.4 ± 3.9           | 63.8 ± 3.9           | <0.001            |
| Dyslipidemia (%)            | 1.7 ± 1.2            | 1.6 ± 1.2            | 1.0 ± 1.2            | 3.5 ± 1.2            | 0.19              |
| Triglycerides (mg/dL)       | 99.0 ± 6.6           | 118.3 ± 6.3          | 148.1 ± 6.3          | 186.7 ± 6.4          | <0.001            |
| Calculated LDL-C (mg/dL)    | 102.7 ± 1.0          | 98.3 ± 0.9           | 93.3 ± 0.9           | 84.5 ± 0.9           | <0.001            |
| Direct LDL-C (mg/dL)        | 77.5 ± 1.2           | 88.3 ± 1.2           | 98.1 ± 1.2           | 114.0 ± 1.2          | <0.001            |
| Small dense LDL-C / calculated LDL-C ratio (%) | 10.4 ± 1.3          | 21.7 ± 1.3           | 30.0 ± 1.3           | 47.3 ± 1.3           | <0.001            |
| Small dense LDL-C / direct LDL-C ratio (%) | 16.7 ± 0.5          | 21.8 ± 0.4           | 26.4 ± 0.4           | 35.0 ± 0.5           | <0.001            |
| Large buoyant LDL-C (mg/dL)§ | 63.9 ± 1.1           | 69.2 ± 1.1           | 72.7 ± 1.0           | 74.2 ± 1.1           | <0.001            |
| VLDL-C (mg/dL)              | 24.5 ± 1.3           | 29.3 ± 1.2           | 34.9 ± 1.2           | 44.8 ± 1.2           | <0.001            |
| LDL-triglycerides (mg/dL)   | 8.2 ± 0.8            | 9.5 ± 0.7            | 12.7 ± 0.7           | 16.9 ± 0.7           | <0.001            |
| HDL3-C (mg/dL)              | 15.7 ± 0.4           | 15.3 ± 0.4           | 14.4 ± 0.4           | 13.2 ± 0.4           | <0.001            |
| HDL2-C (mg/dL) ‡            | 46.5 ± 0.4           | 47.0 ± 0.4           | 47.8 ± 0.4           | 49.0 ± 0.4           | <0.001            |
| Lipoprotein(a) (mg/dL)      | 11.6 ± 1.0           | 11.2 ± 0.9           | 10.4 ± 0.9           | 7.2 ± 1.0            | <0.001            |
| Adiponectin (µg/dL)         | 9.2 ± 0.4            | 8.2 ± 0.4            | 8.1 ± 0.4            | 7.2 ± 0.4            | <0.001            |
| High sensitivity CRP (mg/L) | 0.62 ± 0.07          | 0.68 ± 0.07          | 0.71 ± 0.07          | 0.82 ± 0.07          | <0.01             |
| Mean cIMT at baseline (mm)  | 0.69 ± 0.01          | 0.70 ± 0.01          | 0.69 ± 0.01          | 0.69 ± 0.01          | 0.95              |
| Mean cIMT progression (mm)  | 0.31 ± 0.04          | 0.33 ± 0.04          | 0.34 ± 0.04          | 0.41 ± 0.04          | <0.01             |

‡Adjusted for standard ASCVD risk factors included age, sex, systolic blood pressure, total cholesterol, high density lipoprotein cholesterol, current smoking, history of diabetes, and hypertension treatment.

§Data are shown as median [25% quartile, 75% quartile] or number (%) for unadjusted variables.

¶Parameter is calculated using the following Friedewald equation: (total cholesterol – HDL-C) – (triglycerides/5).

*Parameter is calculated using the following equation: LDL-C – small dense LDL-C.

**Parameter is calculated using the following equation: total cholesterol – HDL-C.

††Parameter is calculated using the following equation: HDL-C – HDL3-C.

*P values <0.05 compared with Quartile 1.

**P values <0.01 compared with Quartile 1.

***P values <0.001 compared with Quartile 1.

LDL-C, low-density lipoprotein cholesterol; ASCVD, atherosclerotic cardiovascular disease; HDL-C, high-density lipoprotein cholesterol; VLDL-C, very low-density lipoprotein cholesterol; CRP, C reactive protein; cIMT, carotid intimal medial thickness.

With the highest sdLDL-C levels were also more likely to have the highest prevalence of alcohol drinking habits, and the highest values for BMI, diastolic blood pressure, direct LDL-C, sdLDL-C/HDLC ratio, lbLDL-C, LDL-TG, triglycerides, and hsCRP (all P < 0.05). Interestingly, they were likely to have lower HDL3-C, but higher HDL2-C levels. The mean cIMT progression significantly increased with sdLDL-C quartiles (P < 0.01). However, mean cIMT levels at baseline were not different across sdLDL-C quartiles.
Adding TG to the controlling factors did not change those correlations. In addition, those results were not different when excluding 187 premenopausal women.

The correlations between sdLDL-C and other lipoproteins and hsCRP are shown in Supplementary Fig. 1. The positive correlations with sdLDL-C were found with direct LDL-C, triglycerides, non-HDL-C, LDL-TG, lbLDL-C, calculated LDL-C, total cholesterol, and hsCRP. HDL-C, HDL2-C, HDL3-C, adiponectin, and Lp(a) showed negative correlations with sdLDL-C.

### 3.4 sdLDL-C Levels and cIMT Progressions

We assessed the association of sdLDL-C levels with cIMT progressions, stratified by direct LDL-C levels (direct LDL-C ≤ 100 mg/dL and > 100 mg/dL) (Fig. 1). In these analyses, the mean cIMT change levels were adjusted for standard CVD risk factors such as age, gender, smoking, systolic blood pressure, hypertension treatment, diabetes, total cholesterol, and HDL-C. Mean cIMT progression in both groups, with direct LDL-C levels ≤ 100 mg/dL and >100 mg/dL, significantly increased in accordance with higher sdLDL-C quartiles (P for trend < 0.01 and < 0.001, respectively). Among subjects with direct LDL-C levels ≤ 100 mg/dL, individuals with the highest sdLDL-C quartile had significantly increased cIMT levels than those with the lowest sdLDL-C quartile (P<0.05), but this was not the case for those with 2nd and 3rd sdLDL-C quartiles. Among the high LDL-C group, individuals with the highest sdLDL-C quartile had significantly increased cIMT levels than those with all other sdLDL-C quartiles (all P<0.05). Individuals with the highest sdLDL-C quartile in the high LDL-C group had significantly increased cIMT levels than those with all other groups (all P<0.05).

cIMT, carotid intimal medial thickness; sdLDL-C, small dense low-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; CVD, cardiovascular disease.

### 3.5 sdLDL-C/LDL-C Ratios and cIMT Progressions

We also assessed the association of sdLDL-C/LDL-C ratios with cIMT progressions.
and disability in the world\textsuperscript{11}, and cIMT levels are thought to be a good surrogate marker\textsuperscript{22-24}. Thus, understanding risk factors for cIMT progression may be helpful for formulating an optimal therapy for CVD prevention. In the current study, we examined the association between atherogenic lipoproteins levels and cIMT changes in a general Japanese prospective observational study cohort, with five years of follow-up, using automated homogeneous sdLDL-C, direct LDL-C, LDL-TG, Lp(a), and HDL3-C assays. Elevated plasma sdLDL-C and direct LDL-C levels, and sdLDL-C/LDL-C ratio were significantly associated with cIMT progression after controlling for standard CVD risk factors (estimated values were 0.227, 0.306, and 0.455, respectively). Moreover, even in subjects with direct LDL-C levels less than 100 mg/dL, only elevated sdLDL-C levels were significantly associated with cIMT progression \((P\text{ for trend} < 0.01)\). It is well known that sdLDL-C is related to TG, and lipid profiles may differ between pre- and postmenopausal women; however, our results did not change by adding TG to controlling factors or excluding premenopausal women.

4. Discussion

CVD remains one of the leading causes of death and disability in the world\textsuperscript{11}, and cIMT levels are thought to be a good surrogate marker\textsuperscript{22-24}. Thus, understanding risk factors for cIMT progression may be helpful for formulating an optimal therapy for CVD prevention. In the current study, we examined the association between atherogenic lipoproteins levels and cIMT changes in a general Japanese prospective observational study cohort, with five years of follow-up, using automated homogeneous sdLDL-C, direct LDL-C, LDL-TG, Lp(a), and HDL3-C assays. Elevated plasma sdLDL-C and direct LDL-C levels, and sdLDL-C/LDL-C ratio were significantly associated with cIMT progression after controlling for standard CVD risk factors (estimated values were 0.227, 0.306, and 0.455, respectively). Moreover, even in subjects with direct LDL-C levels less than 100 mg/dL, only elevated sdLDL-C levels were significantly associated with cIMT progression \((P\text{ for trend} < 0.01)\). It is well known that sdLDL-C is related to TG, and lipid profiles may differ between pre- and postmenopausal women; however, our results did not change by adding TG to controlling factors or excluding premenopausal women.

Elevated LDL-C levels are associated with CVD events\textsuperscript{9}, and lowering LDL-C, along with lifestyle...
There are some limitations in this study. The cohort size was relatively small, and all participants were native Japanese. Thus, a larger study with various ethnicities will be necessary to confirm our findings. In addition, direct sdLDL-C measurement are not widely available in Japan. It is necessary to promote direct sdLDL-C measurement’s clinical usefulness in preventive healthcare medicine. Moreover, the subjects included in this study received no cholesterol lowering medications during the baseline and follow-up surveys. We have to assess whether lowering sdLDL-C levels modulates cIMT levels in a study including subjects receiving cholesterol lowering medications.

5. Conclusions

In conclusion, both LDL-C and sdLDL-C levels measured with homogenous automated assays were significantly associated with cIMT progression, and sdLDL-C had a stronger relationship with cIMT progression than LDL-C. Our results support the concept that direct sdLDL-C and LDL-C should be measured in subjects with high CVD risk as well as those with established CVD in order to formulate an optimal therapy for CVD prevention.

Acknowledgement

The authors thank Katalin V. Horvath for excellent technical assistance and Drs. Mosaburo Kainuma, Eiichi Ogawa, Kazuhiro Toyota, Koji Takayama, Fujiko Kaseida-Mitsumoto, Satoshi Hiramine, Kazuya Ura, and Ayaka Komori for their efforts in collecting data and checking the questionnaires. The authors also appreciate Denka-Seiken Co., Ltd. for kindly providing their lipoprotein assay kits.

Disclosure of Conflict of Interest

The authors have nothing to declare with regard to conflict of interest.

Grant Supports

This study was funded by the Japan Multi-Institutional Collaborative Cohort Study (J-MICC Study), Grants-in-Aid for Scientific Research on Priority Areas of Cancer [No. 17015018] and Innovative Areas [No. 22150001] and by JSPS KAKENHI Grants [No. 16H06277] from the Japanese Ministry of Education, Culture, Sports, Science and Technology. H.I. was supported by the Japan Heart Foundation/Bayer Yakuhin Research Grant Abroad Program, Tokyo.
Japan and Denka Seiken Co., Ltd., Niigata, Japan. E.J.S. and B.F.A. were supported by the U.S. Department of Agriculture - Agricultural Research Service under Specific Cooperative Agreements #58-1950-0-014 and #58-1950-4-003, and Project Grant P50 HL083813-01 from the National Institutes of Health.

Authors' Contributions

H.I., E.J.S., N.F., M.M., and J.H. designed and conducted this study. H.I., N.F., M.M., and J.H. collected data and samples. H.I., Y.Y., and B.F.A. performed the experiments. H.I., E.J.S., and N.F. analyzed the data and contributed to writing the paper. All authors critically revised the manuscript for important intellectual content and approved the final version of the manuscript.

References

1) Global Health Estimates 2016: Deaths by Cause, Age, Sex, by Country and by Region, 2000-2016. Geneva, World Health Organization; 2018
2) Goff DC Jr, Lloyd-Jones DM, Bannett G, Coady S, D'Agostino RB Sr, Gibbons R, Greenland P, Lackland DT, Levy D, O'Donnell CJ, Robinson JG, Schwartz JS, Sher ST, Smith SC Jr, Sorlie P, Stone NJ, and Wilson PW; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. AHA/ACC guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol, 2014; 63: 2935-2959
3) Lloyd-Jones DM, Morris PB, Ballantyne CM, Birther KK, Daly DD Jr, DePalma SM, Minissian MB, Orringer CE, and Smith SC Jr. 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol, 2017; 70: 1785-1822
4) Friedewald WT, Levy RI, and Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem, 1972; 18: 499-502
5) Martin SS, Blaha MJ, Elshazy MB, Toth PP, Kivovich PO, Blumenthal RS, and Jones SR. Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. JAMA, 2013; 310: 2061-2068
6) McNamara JR, Cohn JS, Wilson PW, and Schaefer EJ. Calculated values for low-density lipoprotein cholesterol in the assessment of lipid abnormalities and coronary disease risk. Clin Chem, 1990; 36: 36-42
7) Okada M, Matsui H, Ito Y, Fujiwara A, and Inano K. Low density lipoprotein cholesterol can be chemically measured; a new superior method. J Lab Clin Med, 1998; 132: 195-201
8) Sakae T, Hirano T, Yoshino G, Sakai K, Takeuchi H, and Adachi M. Reactions of direct LDL-cholesterol assays with pure LDL fraction and IDL: comparison of three homogeneous methods. Clin Chim Acta, 2000; 295: 97-106
9) Otokozawa S, Ai M, Asztalos BF, White CC, Demissie-Banjav S, Cupples LA, Nakajima K, Wilson PW, and Schaefer EJ. Direct assessment of plasma low density lipoprotein and high density lipoprotein cholesterol. Atherosclerosis, 2010; 213: 251-255
10) Griffin BA. Lipoprotein atherogenicity: an overview of current mechanisms. Proc Nutr Soc, 1999; 58: 163-169
11) Campos H, Genest JJ, Blijlevens E, McNamara JR, Jenner JL, Ordovas JM, Wilson PW, and Schaefer EJ. Low density lipoprotein particle size and coronary artery disease. Arterioscler Thromb, 1992; 12: 187-195
12) McNamara JR, Jenner JL, Li Z, Wilson PWF, and Schaefer EJ. Change in low density lipoprotein particle size in associated with change in plasma triglyceride concentration. Arterioscler Thromb, 1992; 12: 1284-1290
13) Campos H, Blijlevens E, McNamara JR, Ordovas JM, Wilson PWF, and Schaefer EJ. LDL particle size distribution: results from the Framingham Offspring Study. Arterioscler Thromb, 1992; 12: 1410-1419
14) Hirano T, Ito Y, Saegusa H, and Yoshino G. A novel and simple method for quantification of small dense LDL. J Lipid Res, 2003; 44: 2193-2201
15) Ito Y, Fujimura M, Ohta M, and Hirano T. Development of a homogeneous assay for measurement of small dense LDL cholesterol. Clin Chem, 2011; 57: 57-65
16) Koba S, Yokota Y, Hirano T, Ito Y, Ban Y, Tsunoda F, Sato T, Shoji M, Suzuki H, Geshi E, Kobayashi Y, and Katagiri T. Small LDL-cholesterol is superior to LDL-cholesterol for determining severity of coronary atherosclerosis. J Atheroscler Thromb, 2008; 15: 250-260
17) Ai M, Otokozawa S, Asztalos BF, Ito Y, Nakajima K, White CC, Cupples LA, Wilson PW, and Schaefer EJ. Small dense LDL cholesterol and coronary heart disease: results from the Framingham Offspring Study. Clin Chem, 2010; 56: 967-976
18) Arai H, Kokubo Y, Watanabe M, Sawamura T, Ito Y, Minagawa A, Okamura T, and Miyamoto Y. Small dense low-density lipoprotein cholesterol can predict incident cardiovascular disease in an urban Japanese cohort: the Suita study. J Atheroscler Thromb, 2013; 20: 195-203
19) Hoogeveen RC, Gubatz JW, Sun W, Dodge RC, Crosby JR, Jiang J, Couper D, Virani SS, Kathiresan S, Boerwinkle E, and Ballantyne CM. Small dense LDL cholesterol and coronary heart disease: results from the Framingham Offspring study. Arterioscler Thromb Vasc Biol, 2014; 34: 1069-1077
20) Tsai MY, Steffen BT, Guan W, McClelland RL, Warnick R, McConnell J, Hoefner DM, and Remaley AT. New automated assay of small dense low-density lipoprotein cholesterol identifies risk of coronary heart disease: the Multi-Ethnic Study of Atherosclerosis. Arterioscler Thromb Vasc Biol, 2014; 34: 196-201
21) Hsu SHJ, Jang MH, Torng PL, and Su TC. Positive association between small dense low-density lipoprotein cho-
lesterol concentration and biomarkers of inflammation, thrombosis, and prediabetes in non-diabetic adults. J Atheroscler Thromb, 2019; 26: 624-635
22) Burke GL, Evans GW, Riley WA, Sharrett AR, Howard G, Barnes RW, Rosamond W, Crow RS, Rautaharju PM, and Heiss G. Arterial wall thickness is associated with prevalent cardiovascular disease in middle-aged adults. The Atherosclerosis Risk in Communities (ARIC) Study. Stroke, 1995; 26: 386-391
23) Raitakari OT, Juonala M, Kähönen M, Tahttonen L, Laitinen T, Mäki-Torkko N, Järvisalo MJ, Uhari M, Jokinen E, Rönnemaa T, Akkerblom HK, and Viikari JS. Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study. JAMA, 2003; 290: 2277-2283
24) Iino H, Okano T, Daisaki K, Chigira M, Nakano T, Mizo N, Yamazaki T, Kurano M, Yatomi Y, Sumi Y, Sasano T, and Miyata T. Usefulness of carotid arterial strain values for evaluating the arteriosclerosis. J Atheroscler Thromb, 2019; 26: 476-487
25) Castelli WP, Anderson K, Wilson PW, and Levy D. Lipids in Japanese subjects. Clin Chim Acta, 2015; 442: 110-114
26) Iino H, Okano T, Daimon M, Sasaki K, Chigira M, Nakano T, Mizo N, Yamazaki T, Kurano M, Yatomi Y, Sumi Y, Sasano T, and Miyata T. Usefulness of carotid arterial strain values for evaluating the arteriosclerosis. J Atheroscler Thromb, 2019; 26: 476-487
27) Steffen BT, Guan W, Remaley AT, Stein JH, Tattersall MC, Kaufman J, and Tsai MY. Apolipoprotein B is associated with carotid atherosclerosis progression independent of individual cholesterol measures in a 9-year prospective study of Multi-Ethnic Study of Atherosclerosis participants. J Clin Lipidol, 2017; 11: 1181-1191
28) Maeda S, Nakaniishi S, Yoneda M, Awaya T, Yamane T, Hirano T, and Kohono N. Associations between small dense LDL, HDL subfractions (HDL2, HDL3) and risk of atherosclerosis in Japanese-Americans. J Atheroscler Thromb, 2012; 19: 444-452
29) Lampraca-Montealegre JA, Astor BC, McClelland RL, de Boer IH, Burke GL, Sibby CT, O'Leary D, Sharrett AR, and Szklowski C. CKD, plasma lipids, and common carotid intima-media thickness: results from the multi-ethnic study of atherosclerosis. Clin J Am Soc Nephrol, 2012; 7: 1777-1785
30) Gentile M, Panico S, Mattiello A, Ubaldi S, Iannuzzi G, De Michele M, Iannuzzi A, and Rubba P. Association between small dense LDL and early atherosclerosis in a sample of menopausal women. Clin Chim Acta, 2013; 426: 1-5
31) Aoki T, Yagi H, Sumino H, Tsunekawa K, Araki O, Kimura T, Nara M, Ogawa T, Nakajima K, and Murakami M. Relationship between carotid artery intima-media thickness and small dense low-density lipoprotein cholesterol concentrations measured by homogenous assay in Japanese subjects. Clin Chim Acta, 2015; 442: 110-114
32) Furusyo N, Koga T, Ai M, Otokozawa S, Kohzuma T, Ikezaki H, Schaefer EJ, and Hayashi J. The serum undercarboxylated osteocalcin level and the diet of a Japanese population: Results from the Kyushu and Okinawa Population Study of Atherosclerosis Risk in Young Finns Study and the Framingham Offspring Study. J Clin Lipidol, 2017; 11: 348-356
33) Ikezaki H, Furusyo N, Jacques PF, Shimizu M, Murata M, Schaefer EJ, Urita Y, and Hayashi J. Higher dietary cholesterol and ω-3 fatty acid intakes are associated with a lower success rate of Helicobacter pylori eradication therapy in Japan. Am J Clin Nutri, 2017; 106: 581-588
34) Ikezaki H, Ai M, Schaefer EJ, Otokozawa S, Asztalos BF, Nakajima K, Zhou Y, Liu CT, Jacques PF, Cupples LA, and Furusyo N. Cardiovascular disease prevalence and insulin resistance in the Kyushu-Okinawa Population Study and the Framingham Offspring Study. J Clin Lipidol, 2017; 11: 348-356
35) Ito Y, Ohta M, Ikezaki H, Hiranou Y, Machida A, Schaefer EJ, and Furusyo N. Development and Population Results of a Fully Automated Homogeneous Assay for LDL Tri-glyceride. J App Lab Med, 2018; 2: 746-756
36) Lamon-Fava S, Marcovina SM, Albers JJ, Kennedy H, Deluca C, White CC, Cupples LA, McNamara JR, Semon LJ, Bongard V, and Schaefer EJ. Lipoprotein(a) levels, apo(a) isoform size, and coronary heart disease risk in the Framingham Offspring Study. J Lipid Res, 2011; 52: 1181-1187
37) Ito Y, Satoh N, Ishii T, Kumakura J, and Hiranou T. Development of a homogeneous assay for measurement of high-density lipoprotein-subclass cholesterol. Clin Chim Acta, 2014; 427: 86-93
38) Ikezaki H, Fisher VA, Lim E, Ai M, Liu CT, Cupples LA, Nakajima K, Asztalos BF, Furusyo N, and Schaefer EJ. Direct versus calculated low-density lipoprotein cholesterol and C reactive protein in cardiovascular disease risk assessment in the Framingham Offspring Study. Clin Chem, 2019; 65: 1102-1114
39) Yanase T, Nasu S, Mukuta Y, Shimizu Y, Nishihara T, Okabe T, Nomura M, Inoguchi T, and Nawata H. Evaluation of a new carotid intima-media thickness measurement by B-mode ultrasonography using an innovative measurement software, intimascope. Am J Hypertens, 2006; 19: 1206-1212
40) Wada S, Koga M, Toyoda K, Minematsu K, Yasaka M, Nagai Y, Aoki S, Nezu T, Hosomi N, Kagimura T, Orihara G, Kaimiyama K, Suzuki R, Ohtsuki T, Maruyama H, Kitagawa K, Uchiyama S, and Matsumoto M; the Japan Statin Treatment Against Recurrent Stroke (J-STARS) Echo Study Collaborators. Factors associated with intima-media complex thickness of the common carotid artery in Japanese noncardioembolic stroke patients with hyperlipidemia: The J-STARS Echo Study. J Atheroscler Thromb, 2018; 25: 359-373
41) Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, Braunwald E, and Sabatine MS. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. JAMA, 2016; 316: 1289-1297
42) Writing Committee; Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Daly DD Jr, DePalm SM, Minissian MB, Orringer CE, and Smith SC Jr. 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiol-
44) Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel members. An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia - full report. J Clin Lipidol, 2014; 8: 29-60
45) Thongtang N, Diffenderfer MR, Ooi EM, Barrett PHR, Turner SM, Le NA, Brown WV, and Schaefer EJ. Metabolism and proteomics of large and small dense LDL in combined hyperlipidemia. Effects of rosvastatin. J Lipid Res, 2017; 58: 1315-1324
46) Hurt-Camejo E, Olsson U, Wiklund O, Bondjers G, and Camejo G. Cellular consequences of the association of apoB lipoproteins with proteoglycans. Potential contribution to atherogenesis. Arterioscler Thromb Vasc Biol, 1997; 17: 1011-1017
Supplementary Fig. 1. Correlations between sdLDL-C and other lipoproteins and hsCRP

This figure shows scatter plots between sdLDL-C and other lipoproteins and hsCRP. According to Spearman's \( r \) values, positive correlations between sdLDL-C were found in order direct LDL-C, triglycerides, non-HDL-C, LDL-TG, large buoyant LDL-C, calculated LDL-C, total cholesterol, and hsCRP; HDL-C, HDL2-C, HDL3-C, adiponectin, and Lp(a) showed negative correlations between sdLDL-C.

sdLDL-C, small dense low-density lipoprotein cholesterol; hsCRP, high sensitivity C reactive protein; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-TG, low-density lipoprotein triglycerides; Lp(a), lipoprotein(a).
Spearman’s R = 0.652
P < 0.0001

Spearman’s R = -0.158
P < 0.0001

Spearman’s R = 0.684
P < 0.0001

Spearman’s R = -0.316
P < 0.0001

Spearman’s R = -0.288
P < 0.0001

Spearman’s R = 0.268
P < 0.0001

(Cont. Supplementary Fig. 1.)
Spearman’s R = -0.063  
P = 0.03

Spearman’s R = 0.271  
P < 0.0001

(Cont. Supplementary Fig. 1.)